News
BUSINESSWIRE
Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement
12/2021
GLOBE NEWSWIRE
CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed and Recurrent Urothelial Cancer Patients
6/2021
The Fosciclopirox Story
DD NEWS
A good start for fosciclopirox
3/2020
GLOBE NEWSWIRE
CicloMed Presents New Oncology Data from Phase I Trial with Fosciclopirox at 2020 ASCO Genitourinary Cancers Symposium
2/13/2020
GLOBE NEWSWIRE
CicloMed Expands Fosciclopirox Phase 1 Trial to Include Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
12/3/2019
GLOBE NEWSWIRE
CicloMed Announces ASCO 2018 Presentation on Clinical Trial for Ciclopirox Prodrug, Under Development for Bladder Cancer
5/31/2018
FIERCE BIOTECH
Antifungal ‘prodrug’ shows promise in bladder cancer: AACR
4/16/2018
GLOBE NEWSWIRE
CicloMed Announces Presentation of Preclinical Evidence for its Bladder Cancer Agent at AACR 2018 Meeting
4/12/2018
DRUG DEVELOPMENT & DELIVERY
CicloMed Announces First Patient Dosed With Ciclopirox Prodrug in Phase I Trial
3/6/2018
GLOBE NEWSWIRE
CicloMed Announces First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid Tumors
2/28/2018
The University of Kansas Cancer Center
CicloMed Announces FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder Cancer
10/11/2017
University of kansas medical center
IAMI partners with BioNovus to develop bladder cancer drug
5/9/2016
Kansas City business journal
KC biotech developing KU cancer drug clears big FDA hurdle
10/11/2017
GLOBE NEWSWIRE
FDA gives CicloMed permission to proceed to phase I clinical trials of Ciclopirox Prodrug in cancer patients with advanced solid tumors
10/11/2017
Scientific Publications
SPRINGER NATURE
Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex
6/23/2021
AACR VIRTUAL ANNUAL MEETING 2020
(Abstract 6405)
Fosciclopirox Suppresses Growth of High-Grade Urothelial Cancer by Targeting Notch Signaling
6/23/2020
ASCO GENITOURINARY CANCERS SYMPOSIUM 2020
(ABSTRACT 518)
Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors
2/14/2020
AACR 2018 POSTER
Bench-to-Bedside Translation of Ciclopirox Prodrug for the Treatment of Non-Muscle Invasive and Muscle-Invasive Bladder Cancer
4/18/2018
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Title: Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment for Urothelial Cancers in Rats and Dogs
Date 5/21/2019
ASCO GENITOURINARY CANCERS SYMPOSIUM 2020
(ABSTRACT TPS604)
Window of opportunity trial to characterize the safety, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in cisplatin-ineligible muscle invasive bladder cancer patients
2/14/2020
ASCO 2018 POSTER
Title: Safety, Dose Tolerance, Pharmacokinetics and Pharmacodynamics Study of CPX-POM in Patients with Advanced Solid Tumors
Date 6/4/2018
ASCO 2018 ABSTRACT TPS2618
Title: Safety, Dose Tolerance, Pharmacokinetics and Pharmacodynamics Study of CPX-POM in Patients with Advanced Solid Tumors
Date 6/4/2018
ALBERT INSTITUTE
Product Development-Focused Translational Research: A Collaboration Model to Bring New Treatments to Bladder Cancer Patients
9/15/2017
DRUG REPOSITIONING CONFERENCE
Public-Private Partnership to Bring New Treatments to Patients
6/28/2017
AACR 2015: ABSTRACT 1895
Ciclopirox prodrug for the prevention and therapy of non-muscle invasive bladder cancer
4/18/2015
AACR 2018: ABSTRACT 5882
Bench-to-bedside translation of ciclopirox prodrug for the treatment of non-muscle invasive and muscle-invasive bladder cancer
4/18/2018
Additional Resources
Bladder Cancer Advocacy Network (BCAN) – devoted to advancing bladder cancer research and supporting those impacted by the disease
Leo and Anne Albert Institute for Bladder Cancer Care and Research – with the mission to advance knowledge of bladder cancer and the care of those with the disease
Institute for Advancing Medical Innovation (IAMI) – Changing the standard of care for pediatric, adolescent and adult patients living with diseases including cancer and rare diseases
The University of Kansas Cancer Center
Working toward a world without cancer, through world-class research, partnerships and patient care